Johnson & Johnson (JNJ) Quality Analysis

Johnson & Johnson exhibits a high-quality financial profile, scoring well on the framework's key indicators. The company's profitability is exceptional, with a 28.5% profit margin and a 26.8% operating margin, indicating efficient operations. Its Return on Equity of 32.9% far exceeds the 15-20% high-quality threshold, demonstrating superb capital efficiency. The balance sheet is conservative with a manageable Debt/Equity ratio of 0.59, comfortably below the 1.0x caution level. Revenue growth of 9.1% YoY is consistent, though not in the double-digit range often associated with high-growth moat companies. The 3.4% Free Cash Flow Yield is positive but modest, translating to a P/FCF of approximately 29x, which requires evaluation against growth. The business benefits from a durable moat, likely scoring highly on criteria like Brand & Culture, Regulatory Barriers (via patents), and possibly Technology Leadership in pharmaceuticals and medical devices. This moat supports its high and stable returns. Compared to peers in large-cap pharma, J&J's profitability and ROE are typically at the top tier, reflecting its diversified healthcare model and strong competitive position. The primary consideration for a value investor is that this quality is well-recognized, with the current price above the GoodMoat target of $210.09, suggesting a marginal or unfavourable margin of safety despite the strong business fundamentals.